2024-01-01
Deubiquitination of CIB1 by USP14 promotes lenvatinib resistance via the PAK1-ERK1/2 axis in hepatocellular carcinoma
2024-01-01 • Minghao Xu, Zheng Yi-min, Bu-Gang Liang, Wenxin Xu, Jun Cao, Pei Wang, Zi-Ying Dong, Chenhao Zhou, Hui‐Chuan Sun, Ning Ren, Ai‐Wu Ke, Ying‐Hao Shen
<b>Background:</b> Lenvatinib is the most common multitarget receptor tyrosine kinase inhibitor for the treatment of advanced hepatocellular carcinoma (HCC). Acquired resistance to lenvatinib is one of the major factors leading to the failure of HCC treatment, but the underlying mechanism has not been fully characterized. <b>Methods:</b> We established lenvatinib-resistant cell lines, cell-derived xenografts (CDXs) and patient-derived xenografts (PDXs) and obtained lenvatinib-resistant HCC tumor tissues for furthe…